Filing status
- Accounts due
- 31 December 2027
- Last accounts
- 31 March 2026
- Conf. stmt due
- 25 March 2027
- Last conf. stmt
- 11 March 2026
Acionna Therapeutics Ltd
- Incorporated
- 12 March 2025 (1 year)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- James BilslandBryan Paul MorganDamhnait Roisin Nicamhlaoibh
- Owned by
- Accounts type
- Small
- Region
- East of England
- Address
- Burnham HouseSplash LaneHuntingdonPE28 2AF
Officers 5 active
Officer details are public data from the Companies House register.
Bilsland, James
Director · Appointed 14 July 2025
British
Born July 1971 (55)
Morgan, Bryan Paul, Dr
Director · Appointed 24 April 2025
British
Born November 1955
Nicamhlaoibh, Damhnait Roisin, Dr
Director · Appointed 24 April 2025
Irish
Born May 1972 (54)
British
Born September 1973 (53)
Director · Appointed 12 March 2025
Also at Scripta Therapeutics Limited · more companies
British
Born May 1971 (55)
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 29 April 2025
Owns 50–75% of shares
Holds 50–75% of voting rights
Public Limited Company
Reg. no. 09093331
Former controllers (3)
29 April 2025
Ceased Bryan Paul Morgan — Owns 25–50% of shares
29 April 2025
Ceased Wioleta Zelek — Owns 25–50% of shares
25 March 2025
Ceased Oxford Science Enterprises PLC — Owns 75–100% of shares
Group structure 17 shown
Ownership group derived from the Companies House PSC register
Acionna Therapeutics Ltd This company Owns 50–75% of shares
Animal Dynamics Limited Owns 50–75% of shares
Archangel Lightworks Ltd Owns 25–50% of shares
Ascension Earth Resources Ltd Owns 25–50% of shares
Caudal Energy Limited Owns 25–50% of shares
Caudal Morlais Limited Owns 75–100% of shares
Circadian Therapeutics Limited Owns 75–100% of shares
Cora Biosciences Limited Owns 25–50% of shares
Credo Therapies Ltd Owns 50–75% of shares
Densix Limited Owns 25–50% of shares
Dyna Therapeutics Limited Owns 50–75% of shares
Eligentis Limited Owns 25–50% of shares
Evox Therapeutics Limited Owns 25–50% of shares
Fluorok Limited Owns 25–50% of shares
Financials
Balance sheet as at 31 March 2026 · small accounts
- Cash
- £4,227,537
- Current Ratio
- 10.8x
Balance sheet detail
| 2026 | |
|---|---|
| Fixed Assets | £102,615 |
| Current Assets | £4,819,960 |
| Debtors | £592,423 |
| Cash | £4,227,537 |
| Creditors (< 1 year) | £446,413 |
| Net Current Assets | £4,373,547 |
| Shareholder Funds | £4,476,162 |
Filings
Filing history not loaded yet. See it on Companies House
Some other companies at this address
Other companies in this industry
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →